Nanoviricides has progressed from a pink sheet shell, all the way through two separate uplistings, to now being an NYSE group listed company. NanoViricides has clearly beaten the odds at every turn.
The valuation makes perfect sense, or is in fact even low, because if successful with their pipeline of various viral drug candidates, they will own markets worth BILLIONS of dollars per year in sales. BILLIONS.
NanoViricides has been an SEC FULLY REPORTING company with AUDITED FINANCIALS since 2007.